Company news

Biogen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

June 2, 2024

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

May 29, 2024

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

May 21, 2024

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 15, 2024

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

May 13, 2024

Biogen Reports Progress on Corporate Responsibility Priorities

May 1, 2024

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

April 24, 2024

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 5, 2024

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

March 3, 2024

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

February 22, 2024

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 11, 2024

Biogen to Realign Resources for Alzheimer's Disease Franchise

January 30, 2024

Biogen Appoints Monish Patolawala to its Board of Directors

November 5, 2023

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

October 24, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

October 18, 2023

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 28, 2023

Biogen Completes Acquisition of Reata Pharmaceuticals

September 25, 2023

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 24, 2023

Biogen Appoints Jane Grogan as Head of Research

September 5, 2023

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 3, 2023

Biogen to Acquire Reata Pharmaceuticals

July 27, 2023

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

July 5, 2023

Biogen Announces Changes to Its Board of Directors

June 11, 2023

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 24, 2023

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 11, 2023

Biogen Appoints Adam Keeney as Head of Corporate Development

April 3, 2023

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

March 21, 2023

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

March 15, 2023

Biogen Appoints Chuck Triano as Head of Investor Relations

March 13, 2023

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

March 7, 2023

Biologics License Application for lecanemab designated for Priority Review by china National medical products Administration

February 26, 2023

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 5, 2023

Marketing authorization application for lecanemab as treatment for early Alzheimer's disease accepted by European Medicines Agency

January 25, 2023

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

January 5, 2023

Biogen Names Priya Singhal as Executive Vice President, Head of Development

January 4, 2023

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 3, 2023

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

December 18, 2022

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

December 8, 2022

Biogen Names Christopher Viehbacher President and Chief Executive Officer

November 9, 2022

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

October 16, 2022

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

September 29, 2022

Lecanemab confirmatory phase 3 clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer's disease

September 26, 2022

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

July 25, 2022

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

June 21, 2022

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

June 5, 2022

Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States

June 1, 2022

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

May 30, 2022

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

May 4, 2022

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

March 29, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.